Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes

Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results...

Descripción completa

Detalles Bibliográficos
Autores principales: Follo, Matilde Y., Pellagatti, Andrea, Armstrong, Richard N., Ratti, Stefano, Mongiorgi, Sara, De Fanti, Sara, Bochicchio, Maria Teresa, Russo, Domenico, Gobbi, Marco, Miglino, Maurizio, Parisi, Sarah, Martinelli, Giovanni, Cavo, Michele, Luiselli, Donata, McCubrey, James A., Suh, Pann-Ghill, Manzoli, Lucia, Boultwood, Jacqueline, Finelli, Carlo, Cocco, Lucio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733710/
https://www.ncbi.nlm.nih.gov/pubmed/30787430
http://dx.doi.org/10.1038/s41375-019-0416-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733710/
https://www.ncbi.nlm.nih.gov/pubmed/30787430
http://dx.doi.org/10.1038/s41375-019-0416-x

Ejemplares similares